Cargando…

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer

Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xuan, Jiachen, Pearson, Richard B., Sanij, Elaine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Author’s Views
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671053/ https://www.ncbi.nlm.nih.gov/pubmed/33235908 http://dx.doi.org/10.1080/23723556.2020.1805256

Ejemplares similares

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
por: Sanij, Elaine, et al.
Publicado: (2020)

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461
por: Son, Jinbae, et al.
Publicado: (2020)

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
por: Yan, Shunfei, et al.
Publicado: (2020)

On your marks, get SET(D1A): the race to protect stalled replication forks
por: Begum, Shabana, et al.
Publicado: (2018)

Overexpression of the Fork Protection Complex: a strategy to tolerate oncogene-induced replication stress in cancer cells
por: Pasero, Philippe, et al.
Publicado: (2019)

Beyond DNA repair: the novel immunological potential of PARP inhibitors
por: Chabanon, Roman M., et al.
Publicado: (2019)

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
por: Quin, Jaclyn, et al.
Publicado: (2016)

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer
por: Cornelison, Robert, et al.
Publicado: (2021)

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma
por: Kang, Chang-Won, et al.
Publicado: (2022)

Priming for tolerance and cohesion at replication forks
por: Branzei, Dana, et al.
Publicado: (2016)

CX3CL1 at the crossroad of EGF signals: Relevance for the progression of ERBB2(+) breast carcinoma
por: Tardáguila, Manuel, et al.
Publicado: (2013)

Never tear us a-PARP: Dealing with DNA lesions during mitosis
por: Schoonen, Pepijn M., et al.
Publicado: (2017)

PARP1 inhibition elicits immune responses against non-small cell lung cancer
por: Juncheng, Pan, et al.
Publicado: (2022)

Termination of DNA replication forks: “Breaking up is hard to do”
por: Bailey, Rachael, et al.
Publicado: (2015)

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

Inhibitors of cell cycle checkpoints and DNA replication cause different responses in normal versus malignant urothelial cells
por: Meuth, Mark
Publicado: (2014)

Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators
por: McLellan, Jessica L., et al.
Publicado: (2012)

The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors
por: Bellone, Matteo, et al.
Publicado: (2013)

Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461
por: Li, Guihong, et al.
Publicado: (2018)

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
por: El Hassouni, Btissame, et al.
Publicado: (2019)

Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461
por: Masud, Tehmina, et al.
Publicado: (2021)

Dicer in action at replication-transcription collisions
por: Ren, Jie, et al.
Publicado: (2015)

Destabilization of the replication fork protection complex disrupts meiotic chromosome segregation
por: Escorcia, Wilber, et al.
Publicado: (2017)

A novel mechanism for the prevention of transcription replication conflicts
por: Canal, Berta, et al.
Publicado: (2018)

Setting the stage for cohesion establishment by the replication fork
por: Bharti, Sanjay Kumar, et al.
Publicado: (2012)

Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling
por: Xu, Xia, et al.
Publicado: (2021)

Non-replicating Toxoplasma gondii reverses tumor-associated immunosuppression
por: Fox, Barbara A, et al.
Publicado: (2013)

CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I
por: Lehman, Stacey L., et al.
Publicado: (2022)

Topoisomerase I prevents transcription-replication conflicts at transcription termination sites
por: Liu, Yaqun, et al.
Publicado: (2020)

New link between the RNA polymerase II-CTD and replication stress
por: Landsverk, Helga B., et al.
Publicado: (2021)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors
por: Lee, Sung-Bau, et al.
Publicado: (2018)

Toward understanding the genetics of regulatory T cells in ovarian cancer
por: DeRycke, Melissa S, et al.
Publicado: (2013)

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
por: Xu, Hong, et al.
Publicado: (2017)

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
por: Pan, Min, et al.
Publicado: (2021)

A transcriptional program associated with cell cycle regulation predominates in the anti-inflammatory effects of CX-5461 in macrophage
por: Wang, Jie, et al.
Publicado: (2022)

Tumor vascularity in ovarian cancer: T cells need breathing room
por: Neilson, David, et al.
Publicado: (2014)

Control of S phase duration: a replication capacity model with E2F transcription at its heart
por: Bertoli, Cosetta, et al.
Publicado: (2021)

Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis
por: Labidi-Galy, Sana Intidhar, et al.
Publicado: (2012)

Sestrin1, a tumor suppressor that can be rescued
por: Donaldson, Maria C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vkkv9vjnhm06em0s12fla04c6n